Avoro Capital Advisors Reduces Stake in Vera Therapeutics

Institutional investor sells 90,000 shares of biotech firm

Mar. 14, 2026 at 7:06am

Got story updates? Submit your updates here. ›

Avoro Capital Advisors LLC, a major institutional investor, has decreased its stake in Vera Therapeutics, Inc. (NASDAQ:VERA) by 1.4% in the third quarter. The firm now owns 6,210,000 shares of the company's stock, making it the 15th largest holding in its portfolio.

Why it matters

Vera Therapeutics is a clinical-stage biotech company focused on developing novel immunotherapies for autoimmune and inflammatory diseases. Institutional investors like Avoro Capital Advisors play a significant role in the company's funding and growth trajectory.

The details

According to a 13F filing with the SEC, Avoro Capital Advisors sold 90,000 shares of Vera Therapeutics during the third quarter. The firm now owns 6,210,000 shares, or 9.73% of the company's outstanding stock, worth approximately $180.5 million.

  • Avoro Capital Advisors sold 90,000 shares of Vera Therapeutics in the third quarter of 2026.

The players

Avoro Capital Advisors LLC

A major institutional investor and hedge fund that owns a significant stake in Vera Therapeutics.

Vera Therapeutics, Inc.

A clinical-stage biotechnology company focused on developing novel immunotherapies for autoimmune and inflammatory diseases.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Avoro Capital Advisors' stake in Vera Therapeutics is noteworthy, as institutional investors play a crucial role in funding and supporting clinical-stage biotech companies like Vera. However, the firm still maintains a sizable position, indicating its continued confidence in the company's long-term potential.